Prognostic Factors in Elderly Patients with Diffuse Large B-Cell Lymphoma and Their Treatment Results

Creative Commons License

ADIYAMAN S. C., ALACACIOĞLU İ., Danyeli A. E., Turkyilmaz D., Sevindik O. G., DEMİRKAN F., ...Daha Fazla

TURKISH JOURNAL OF HEMATOLOGY, cilt.36, sa.2, ss.81-87, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 36 Sayı: 2
  • Basım Tarihi: 2019
  • Doi Numarası: 10.4274/tjh.galenos.2019.2018.0219
  • Dergi Adı: TURKISH JOURNAL OF HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.81-87
  • Anahtar Kelimeler: Lymphoid cell neoplasms, B-Cell neoplasms, Lymphomas, Non-Hodgkin lymphoma, NON-HODGKINS-LYMPHOMA, GERIATRIC ONCOLOGY, CHOP CHEMOTHERAPY, DES LYMPHOMES, IMPACT, RITUXIMAB, CLASSIFICATION, SUBTYPE, TRIAL
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objective: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). The treatment of older NHL patients has always been a struggle; however, treatment statistics have begun showing favorable results similar to those of younger DLBCL patients thanks to newer treatment protocols. Here, we analyze the progress of our own elderly DLBCL patients who were followed between 2000 and 2016 in our center.